Abstract 3936
Background
The Risk of Acute Deterioration (RAD) conceived as the patient status at risk for progression, with severe damage or life-threatening conditions, includes possible progression, emergence or recurrence of serious adverse-events Literature related with physiological parameters such blood pressure, cardiac or respiratory alterations and the capacity for a rapid identification of these RAD as predictors of preventable complications and adverse events The hematological patients with complex processes derived from his tumor, comorbidities and complexity hospitalized, may require admission to Iintensive care or unexpected death. Determine the patient profile that needs prevention and nursing activities and control for the risk of acute deterioration RAD at the centres of the Catalan Institute of Oncology-ICO, for 2018.
Methods
Retrospective multicenter cross-sectional study. Scope: 8 oncological units ICO-L’Hospitalet, ICO-Badalona and ICO-Girona. Data obtained from anonymized registries system of the electronic clinical history of patients.January to December of 2018.
Results
From 6.003 episodes of hospitalized patients, 2.661 contained an indicator of RAD as main nurse diagnostic on register, representing 44.3% of the cases. Observation and intensive surveillance or semi-intensive is fundamental. Nurses’ early identification of RAD and 39.06% needed intensive or semi-surveillance.Total deaths 10.68%. The registration of interventions: systematic control of mental state (77.09%); control of respiratory frequency in 29.14%; simultaneous recording of 5 vital signs (26.60%); 4 vital signs (82.16%); intake/out control (18.67%); record of diuresis (80.86%).
Conclusions
Nurses most performed and registered activities were control of heart rate, blood pressure, Sat. O2, temperature, diuresis and mind alert. Low registration for FR, despite being identified as a key intervention in the early identification of RAD and is omitted or is not registered although being prescribed in care plan. Early detection of physiological changes and the identification of patients RAD are need to provide adequate preventive care and treatment and to ensure continued evaluation that avoid deterioration or its consequences.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1945 - Randomized Phase II Study of Trabectedin/Olaparib Compared to Physician’s Choice in Subjects with Previously Treated Advanced or Recurrent Solid Tumors Harboring DNA Repair Deficiencies.
Presenter: Christoph Heilig
Session: Poster Display session 3
Resources:
Abstract
3021 - Homogenisation of Leftover Surgical Tissue across multiple cancer types: a Feasibility Study (HoLST-F)
Presenter: Lavinia Spain
Session: Poster Display session 3
Resources:
Abstract
2882 - Safety, efficacy, and immune effects of intratumoral tilsotolimod in patients with refractory solid tumors: updated results from ILLUMINATE-101
Presenter: Hani Babiker
Session: Poster Display session 3
Resources:
Abstract
1950 - Phase 1 Dose Escalation of MSC-1, a humanized anti-LIF monoclonal antibody, in patients (pts) with advanced solid tumors: Updated results
Presenter: Erkut Borazanci
Session: Poster Display session 3
Resources:
Abstract
2391 - A phase 1 study of Sym021, an anti-PD-1 antibody (Ab), alone and in combination with Sym022 (anti-LAG-3) or Sym023 (anti-TIM-3)
Presenter: Anna Spreafico
Session: Poster Display session 3
Resources:
Abstract
5692 - FPA150 (B7-H4 antibody) Phase 1 Update in Advanced Solid Tumors: Monotherapy and in Combination with Pembrolizumab
Presenter: Zev Wainberg
Session: Poster Display session 3
Resources:
Abstract
2416 - MG1124, a novel CEACAM1-targeted monoclonal antibody, has therapeutic potential as a combination partner of PD-1 inhibitors in NSCLC patients
Presenter: Eun Hee Lee
Session: Poster Display session 3
Resources:
Abstract
2661 - Tumor stroma targeting and modulation by OMTX705 ADC, a novel and potent immunotherapeutic treatment of solid tumors.
Presenter: Myriam Fabre
Session: Poster Display session 3
Resources:
Abstract
3681 - Durvalumab + monalizumab, mFOLFOX6, and bevacizumab in patients (pts) with metastatic microsatellite-stable colorectal cancer (MSS-CRC)
Presenter: May Cho
Session: Poster Display session 3
Resources:
Abstract
2664 - Phase (Ph) II study of MBG453 + spartalizumab in patients (pts) with non-small cell lung cancer (NSCLC) and melanoma pretreated with anti–PD-1/L1 therapy
Presenter: Nicholas Mach
Session: Poster Display session 3
Resources:
Abstract